Selected research
Industry Research
IgA Nephropathy Drugs Industry Research Report 2026
Market perspective
The global IgA Nephropathy Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for IgA Nephropathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for IgA Nephropathy Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for IgA Nephropathy Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of IgA Nephropathy Drugs include Calliditas Therapeutics, Chinook Therapeutics, Omeros Corporation, Travere Therapeutics, Vera Therapeutics, Otsuka Pharmaceutical and Novartis International, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global IgA Nephropathy Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
IgA Nephropathy Drugs Market by Company
Calliditas Therapeutics
Chinook Therapeutics
Omeros Corporation
Travere Therapeutics
Vera Therapeutics
Otsuka Pharmaceutical
Novartis International
IgA Nephropathy Drugs Segment by Type
Phase I
Phase II
Phase III
IgA Nephropathy Drugs Segment by Application
Clinical Treatment
Drug Experiment
IgA Nephropathy Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IgA Nephropathy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of IgA Nephropathy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IgA Nephropathy Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of IgA Nephropathy Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of IgA Nephropathy Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of IgA Nephropathy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Phase I
- Phase II
- Phase III
Applications
- Clinical Treatment
- Drug Experiment
Companies covered
- Calliditas Therapeutics
- Chinook Therapeutics
- Omeros Corporation
- Travere Therapeutics
- Vera Therapeutics
- Otsuka Pharmaceutical
- Novartis International
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global IgA Nephropathy Drugs Market Size (2021-2032)
- 2.2.2 Global IgA Nephropathy Drugs Sales (2021-2032)
- 2.2.3 Global IgA Nephropathy Drugs Market Average Price (2021-2032)
- 2.3 IgA Nephropathy Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Phase I
- 2.3.3 Phase II
- 2.3.4 Phase III
- 2.4 IgA Nephropathy Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinical Treatment
- 2.4.3 Drug Experiment
3 Market Competitive Landscape by Manufacturers
- 3.1 Global IgA Nephropathy Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global IgA Nephropathy Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global IgA Nephropathy Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global IgA Nephropathy Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global IgA Nephropathy Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of IgA Nephropathy Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of IgA Nephropathy Drugs, Product Type & Application
- 3.8 Global Manufacturers of IgA Nephropathy Drugs, Established Date
- 3.9 Global IgA Nephropathy Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Calliditas Therapeutics
- 4.1.1 Calliditas Therapeutics Company Information
- 4.1.2 Calliditas Therapeutics Business Overview
- 4.1.3 Calliditas Therapeutics IgA Nephropathy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Calliditas Therapeutics IgA Nephropathy Drugs Product Portfolio
- 4.1.5 Calliditas Therapeutics Recent Developments
- 4.2 Chinook Therapeutics
- 4.2.1 Chinook Therapeutics Company Information
- 4.2.2 Chinook Therapeutics Business Overview
- 4.2.3 Chinook Therapeutics IgA Nephropathy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Chinook Therapeutics IgA Nephropathy Drugs Product Portfolio
- 4.2.5 Chinook Therapeutics Recent Developments
- 4.3 Omeros Corporation
- 4.3.1 Omeros Corporation Company Information
- 4.3.2 Omeros Corporation Business Overview
- 4.3.3 Omeros Corporation IgA Nephropathy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Omeros Corporation IgA Nephropathy Drugs Product Portfolio
- 4.3.5 Omeros Corporation Recent Developments
- 4.4 Travere Therapeutics
- 4.4.1 Travere Therapeutics Company Information
- 4.4.2 Travere Therapeutics Business Overview
- 4.4.3 Travere Therapeutics IgA Nephropathy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Travere Therapeutics IgA Nephropathy Drugs Product Portfolio
- 4.4.5 Travere Therapeutics Recent Developments
- 4.5 Vera Therapeutics
- 4.5.1 Vera Therapeutics Company Information
- 4.5.2 Vera Therapeutics Business Overview
- 4.5.3 Vera Therapeutics IgA Nephropathy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Vera Therapeutics IgA Nephropathy Drugs Product Portfolio
- 4.5.5 Vera Therapeutics Recent Developments
- 4.6 Otsuka Pharmaceutical
- 4.6.1 Otsuka Pharmaceutical Company Information
- 4.6.2 Otsuka Pharmaceutical Business Overview
- 4.6.3 Otsuka Pharmaceutical IgA Nephropathy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Otsuka Pharmaceutical IgA Nephropathy Drugs Product Portfolio
- 4.6.5 Otsuka Pharmaceutical Recent Developments
- 4.7 Novartis International
- 4.7.1 Novartis International Company Information
- 4.7.2 Novartis International Business Overview
- 4.7.3 Novartis International IgA Nephropathy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Novartis International IgA Nephropathy Drugs Product Portfolio
- 4.7.5 Novartis International Recent Developments
5 Global IgA Nephropathy Drugs Market Scenario by Region
- 5.1 Global IgA Nephropathy Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global IgA Nephropathy Drugs Sales by Region: 2021-2032
- 5.2.1 Global IgA Nephropathy Drugs Sales by Region: 2021-2026
- 5.2.2 Global IgA Nephropathy Drugs Sales by Region: 2027-2032
- 5.3 Global IgA Nephropathy Drugs Revenue by Region: 2021-2032
- 5.3.1 Global IgA Nephropathy Drugs Revenue by Region: 2021-2026
- 5.3.2 Global IgA Nephropathy Drugs Revenue by Region: 2027-2032
- 5.4 North America IgA Nephropathy Drugs Market Facts & Figures by Country
- 5.4.1 North America IgA Nephropathy Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America IgA Nephropathy Drugs Sales by Country (2021-2032)
- 5.4.3 North America IgA Nephropathy Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe IgA Nephropathy Drugs Market Facts & Figures by Country
- 5.5.1 Europe IgA Nephropathy Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe IgA Nephropathy Drugs Sales by Country (2021-2032)
- 5.5.3 Europe IgA Nephropathy Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific IgA Nephropathy Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific IgA Nephropathy Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific IgA Nephropathy Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific IgA Nephropathy Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America IgA Nephropathy Drugs Market Facts & Figures by Country
- 5.7.1 South America IgA Nephropathy Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America IgA Nephropathy Drugs Sales by Country (2021-2032)
- 5.7.3 South America IgA Nephropathy Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa IgA Nephropathy Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa IgA Nephropathy Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa IgA Nephropathy Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa IgA Nephropathy Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global IgA Nephropathy Drugs Sales by Type (2021-2032)
- 6.1.1 Global IgA Nephropathy Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global IgA Nephropathy Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global IgA Nephropathy Drugs Revenue by Type (2021-2032)
- 6.2.1 Global IgA Nephropathy Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global IgA Nephropathy Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global IgA Nephropathy Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global IgA Nephropathy Drugs Sales by Application (2021-2032)
- 7.1.1 Global IgA Nephropathy Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global IgA Nephropathy Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global IgA Nephropathy Drugs Revenue by Application (2021-2032)
- 7.2.1 Global IgA Nephropathy Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global IgA Nephropathy Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global IgA Nephropathy Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 IgA Nephropathy Drugs Value Chain Analysis
- 8.1.1 IgA Nephropathy Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 IgA Nephropathy Drugs Production Mode & Process
- 8.2 IgA Nephropathy Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 IgA Nephropathy Drugs Distributors
- 8.2.3 IgA Nephropathy Drugs Customers
9 Global IgA Nephropathy Drugs Analyzing Market Dynamics
- 9.1 IgA Nephropathy Drugs Industry Trends
- 9.2 IgA Nephropathy Drugs Industry Drivers
- 9.3 IgA Nephropathy Drugs Industry Opportunities and Challenges
- 9.4 IgA Nephropathy Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst